adenosine diphosphate has been researched along with rivaroxaban in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Jiang, X; Wong, PC | 1 |
| Bode, C; Diehl, P; Meyer, M; Moser, M; Olivier, CB; Weber, S; Weik, P; Zhou, Q | 1 |
| Honmou, O; Kataoka-Sasaki, Y; Kiyose, R; Magota, H; Nakazaki, M; Oka, S; Onodera, R; Sasaki, M; Ukai, R | 1 |
3 other study(ies) available for adenosine diphosphate and rivaroxaban
| Article | Year |
|---|---|
Apixaban, a direct factor Xa inhibitor, inhibits tissue-factor induced human platelet aggregation in vitro: comparison with direct inhibitors of factor VIIa, XIa and thrombin.
Topics: Adenosine Diphosphate; Anticoagulants; Arginine; Azetidines; Benzimidazoles; Collagen; Dabigatran; Dose-Response Relationship, Drug; Factor VIIa; Factor Xa; Factor Xa Inhibitors; Factor XIa; Humans; Morpholines; Pipecolic Acids; Piperazines; Platelet Aggregation; Platelet Aggregation Inhibitors; Pyrazoles; Pyridines; Pyridones; Rivaroxaban; Sulfonamides; Thiophenes; Thrombin; Thromboplastin; Time Factors | 2010 |
Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors.
Topics: Adenosine Diphosphate; Antithrombins; Arachidonic Acid; Clopidogrel; Dabigatran; Drug Therapy, Combination; Humans; Platelet Aggregation; Platelet Aggregation Inhibitors; Rivaroxaban; Ticlopidine | 2016 |
Pharmacological Difference Between Platelet Aggregations in Cardioembolic Stroke Patients with Direct Oral Anticoagulants: A Pilot Study.
Topics: Adenosine Diphosphate; Administration, Oral; Anticoagulants; Antithrombins; Atrial Fibrillation; Dabigatran; Embolic Stroke; Factor Xa Inhibitors; Humans; Pilot Projects; Platelet Aggregation; Pyridones; Retrospective Studies; Rivaroxaban | 2022 |